AtrophyNCT02868749
Histology and Ultrasound Pilot Study of HA Gels Adipose Tissue
A study testing Hyaluronic Acid filler in people with Atrophy, run by Vandeputte, Joan, M.D. at 2 sites in Belgium.
Trial summary
This study is a single-blind intra-individual comparative study to evaluate the short and medium term tissue response after the injection of 2 brands of hyaluronic acid gels (HA), designed for deep injection, that have been used for several years on a worldwide scale. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Atrophy
- What is being tested?
- Hyaluronic Acid filler
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 2 sitesBelgium
- Study dates
- 22 Mar 2017to 30 Sep 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- patients eligible for and requesting abdominoplasty
- patients eligible for and requesting bilateral breast reduction
Who cannot join
- Patients prone to hypertrophic scarring or keloids
- Hypersensitivity to hyaluronic acid
- Hypersensitivity to lidocaine or amide type local anaesthetics
- Autoimmune disease
- Severe, multiple allergies or anaphylactic shock
- Epilepsy
Show all 15Show fewer
- Heart rhythm disorders
- Porphyria, congenital methemoglobinemia, glucose-6 phosphate dehydrogenase deficiencies, treatment with methaemoglobin-inducing substances.
- Previous streptococcal disease (acute rheumatic fever whether or not with heart valve involvement)
- Patients on medication which slows hepatic metabolism (such as cimetidine, beta-blockers)
- Diabetes requiring insulin treatment
- Major system disease.
- Coagulation disorders. Anticoagulation therapy. Chronic use of acetylsalicylic acid.
- Previous surgery in the areas eligible for injections.
- All contraindications to their surgical treatment (such as pregnancy or lactation).
Trial locations and contacts
2 sites in 1 country.
Belgium2 sites
Universitair Ziekenhuis Brussel
Brussels, B-1090
A.Z. Oudenaarde
Oudenaarde, B-9700
About this study
Official title: Comparative Clinical, Histological and Ultrasound Pilot Study of Two Hyaluronic Acid Gel Fillers, Designed for Deep Injection, in Adipose Tissue
This study is a single-blind intra-individual comparative study to evaluate the short and medium term tissue response after the injection of 2 brands of hyaluronic acid gels (HA), designed for deep injection, that have been used for several years on a worldwide scale.
Read the detailed description
The study will be disclosed to patients who present with an indication for either abdominoplasty or bilateral breast reduction with a Wise pattern skin excision (inverted T inframammary scar) Informed consent will be obtained from volunteers at their next consultation, during which the preoperative preparation is finalised and the surgery is booked.
Participants will receive injections for the first time three weeks to four months before the operation and for the second time five to nine days before the operation, in tissue that will be removed during the surgery.
In each session, through one single access point, a linear retrograde, subcutaneous injection will be performed with 0,5 ml of each of the studied hyaluronic acid gels, each in an opposite direction, each parallel to the skin surface.
Both sessions will be monitored by ultrasound examination. After the injections, the 2 cm of injected area which is most remote from the entrance point of the cannula will be remodelled by finger pressure and tissue pinching, to simulate remodelling as commonly performed after filler injection.
At the beginning of the operation, the injected subcutaneous fat will be removed with the overlying skin, to be sent for histologic examination.
The objective of the histologic examination is to assess the tissue response at one week versus three weeks to four months after the injection, as well as to assess the spread of the products, with and without remodelling after injection.
- Conditions
- Atrophy
- Being tested
- Hyaluronic Acid filler
- Keywords
- Hyaluronic Acid, histology, ultrasound, subcutaneous, adipose tissue
- Medical subject headings
- Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hyaluronic Acid fillerDevice
Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
Hyaluronic Acid fillerDevice
Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
| Study group | Role | What they receive |
|---|---|---|
| Hyaluronic Acid filler 1 for deep injection | Experimental | Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery
Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery Receives: Device: Hyaluronic Acid filler |
| Hyaluronic Acid filler 2 for deep injection | Active comparator | Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery
Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery Receives: Device: Hyaluronic Acid filler |
What is being measured
The primary outcome is the main question the study is designed to answer.
tissue inflammation after injection of hyaluronic acid filler
Presence of lymphocytes and/ or histiocytes around the filler through histologic examination [Yes/No]
Measured: 3 weeks to 4 months after injection
Secondary outcomes (5)
tissue response after injection of hyaluronic acid filler
Presence of lymphocytes and/ or histiocytes and/ or macrophages around the filler through histologic examination [Yes/No]
Measured: 1 week after injection
tissue response after injection and remodelling of hyaluronic acid filler
Presence of lymphocytes and/ or histiocytes and/ or macrophages around the filler through histologic examination [Yes/No]
Measured: 3 weeks to 4 months after injection
tissue response after injection and remodelling of hyaluronic acid filler
Presence of lymphocytes and/ or histiocytes and/ or macrophages around the filler through histologic examination [Yes/No]
Measured: 1 week after injection
filler distribution in tissue
The height and width of the total filler spread [mm]
Measured: 3 weeks to 4 months after injection
filler distribution in tissue
The height and width of the total filler spread [mm]
Measured: 1 week after injection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2016 (estimated)
- Study start22 Mar 2017
- Primary completion11 Apr 2018
- Study completion30 Sep 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for AtrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vandeputte, Joan, M.D.
- Collaborators
- Universitair Ziekenhuis Brussel
- Responsible party
- Sponsor
- Investigators
- Joan H Vandeputte, MD, Principal investigator, A.Z Oudenaarde (Oudenaarde General Hospital)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02868749
- Sponsor's protocol ID
- BVL/JVL
- Status last verified
- Jan 2019
- First submitted
- 27 Jul 2016
- Last updated
- 23 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: pilot study on 5 patients: min, max, average measurements will be published
Publications
Flynn TC, Sarazin D, Bezzola A, Terrani C, Micheels P. Comparative histology of intradermal implantation of mono and biphasic hyaluronic acid fillers. Dermatol Surg. 2011 May;37(5):637-43. doi: 10.1111/j.1524-4725.2010.01852.x. Epub 2011 Jan 27.
PubMed 21272119Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006 Mar;38(3):202-4. doi: 10.1002/lsm.20283.
PubMed 16485276Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg. 2008 Jun;34 Suppl 1:S56-62; discussion S62-3. doi: 10.1111/j.1524-4725.2008.34244.x.
PubMed 18547183Micheels P, Sarazin D, Besse S, Sundaram H, Flynn TC. A blanching technique for intradermal injection of the hyaluronic acid Belotero. Plast Reconstr Surg. 2013 Oct;132(4 Suppl 2):59S-68S. doi: 10.1097/PRS.0b013e31829a02fb.
PubMed 24077012Franca Wanick FB, Almeida Issa MC, Luiz RR, Soares Filho PJ, Olej B. Skin Remodeling Using Hyaluronic Acid Filler Injections in Photo-Aged Faces. Dermatol Surg. 2016 Mar;42(3):352-9. doi: 10.1097/DSS.0000000000000659.
PubMed 26918965Shaw RB Jr, Katzel EB, Koltz PF, Kahn DM, Girotto JA, Langstein HN. Aging of the mandible and its aesthetic implications. Plast Reconstr Surg. 2010 Jan;125(1):332-342. doi: 10.1097/PRS.0b013e3181c2a685.
PubMed 20048624Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007 Jun;119(7):2219-2227. doi: 10.1097/01.prs.0000265403.66886.54.
PubMed 17519724Pilsl U, Rosmarin W, Anderhuber F. The premaxillary space: a location for filler injection? Dermatol Surg. 2014 Mar;40(3):301-4. doi: 10.1111/dsu.12431. Epub 2014 Jan 30.
PubMed 24479675
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Clinical, Histological and Ultrasound Pilot Study of Two Hyaluronic Acid Gel Fillers, Designed for Deep Injection, in Adipose Tissue
- ClinicalTrials.gov ID
- NCT02868749
- Acronym / sponsor ID
- BVL/JVL
- Conditions
- Atrophy
- Keywords
- Hyaluronic Acid, histology, ultrasound, subcutaneous, adipose tissue
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Vandeputte, Joan, M.D.
- Collaborators
- Universitair Ziekenhuis Brussel
- Study start
- 22 Mar 2017 (actual)
- Primary completion
- 11 Apr 2018 (actual)
- Study completion
- 30 Sep 2018 (actual)
- First posted
- 16 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single-blind intra-individual comparative study to evaluate the short and medium term tissue response after the injection of 2 brands of hyaluronic acid gels (HA), designed for deep injection, that have been used for several years on a worldwide scale.
Detailed description
The study will be disclosed to patients who present with an indication for either abdominoplasty or bilateral breast reduction with a Wise pattern skin excision (inverted T inframammary scar) Informed consent will be obtained from volunteers at their next consultation, during which the preoperative preparation is finalised and the surgery is booked.
Participants will receive injections for the first time three weeks to four months before the operation and for the second time five to nine days before the operation, in tissue that will be removed during the surgery.
In each session, through one single access point, a linear retrograde, subcutaneous injection will be performed with 0,5 ml of each of the studied hyaluronic acid gels, each in an opposite direction, each parallel to the skin surface.
Both sessions will be monitored by ultrasound examination. After the injections, the 2 cm of injected area which is most remote from the entrance point of the cannula will be remodelled by finger pressure and tissue pinching, to simulate remodelling as commonly performed after filler injection.
At the beginning of the operation, the injected subcutaneous fat will be removed with the overlying skin, to be sent for histologic examination.
The objective of the histologic examination is to assess the tissue response at one week versus three weeks to four months after the injection, as well as to assess the spread of the products, with and without remodelling after injection.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hyaluronic Acid filler 1 for deep injection | Experimental | Device: Hyaluronic Acid fillerInjection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery |
| Hyaluronic Acid filler 2 for deep injection | Active comparator | Device: Hyaluronic Acid fillerInjection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- patients eligible for and requesting abdominoplasty
- patients eligible for and requesting bilateral breast reduction
Key exclusion criteria (15 listed)
- Patients prone to hypertrophic scarring or keloids
- Hypersensitivity to hyaluronic acid
- Hypersensitivity to lidocaine or amide type local anaesthetics
- Autoimmune disease
- Severe, multiple allergies or anaphylactic shock
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hyaluronic Acid fillerLinear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery. | Device | Hyaluronic Acid filler 1 for deep injection, Hyaluronic Acid filler 2 for deep injection |
| Hyaluronic Acid fillerLinear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery. | Device | Hyaluronic Acid filler 1 for deep injection, Hyaluronic Acid filler 2 for deep injection |
Primary outcome
tissue inflammation after injection of hyaluronic acid filler
Time frame: 3 weeks to 4 months after injection
Presence of lymphocytes and/ or histiocytes around the filler through histologic examination [Yes/No]
5 secondary outcomes
tissue response after injection of hyaluronic acid filler
Time frame: 1 week after injection
tissue response after injection and remodelling of hyaluronic acid filler
Time frame: 3 weeks to 4 months after injection
tissue response after injection and remodelling of hyaluronic acid filler
Time frame: 1 week after injection
filler distribution in tissue
Time frame: 3 weeks to 4 months after injection
filler distribution in tissue
Time frame: 1 week after injection
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2019.
- Background: PubMed 21272119Flynn TC, Sarazin D, Bezzola A, Terrani C, Micheels P. Comparative histology of intradermal implantation of mono and biphasic hyaluronic acid fillers. Dermatol Surg. 2011 May;37(5):637-43. doi: 10.1111/j.1524-4725.2010.01852.x. Epub 2011 Jan 27.
- Background: PubMed 16485276Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006 Mar;38(3):202-4. doi: 10.1002/lsm.20283.
- Background: PubMed 18547183Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg. 2008 Jun;34 Suppl 1:S56-62; discussion S62-3. doi: 10.1111/j.1524-4725.2008.34244.x.
- Background: PubMed 24077012Micheels P, Sarazin D, Besse S, Sundaram H, Flynn TC. A blanching technique for intradermal injection of the hyaluronic acid Belotero. Plast Reconstr Surg. 2013 Oct;132(4 Suppl 2):59S-68S. doi: 10.1097/PRS.0b013e31829a02fb.
- Background: PubMed 26918965Franca Wanick FB, Almeida Issa MC, Luiz RR, Soares Filho PJ, Olej B. Skin Remodeling Using Hyaluronic Acid Filler Injections in Photo-Aged Faces. Dermatol Surg. 2016 Mar;42(3):352-9. doi: 10.1097/DSS.0000000000000659.
- Background: PubMed 20048624Shaw RB Jr, Katzel EB, Koltz PF, Kahn DM, Girotto JA, Langstein HN. Aging of the mandible and its aesthetic implications. Plast Reconstr Surg. 2010 Jan;125(1):332-342. doi: 10.1097/PRS.0b013e3181c2a685.
- Background: PubMed 17519724Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007 Jun;119(7):2219-2227. doi: 10.1097/01.prs.0000265403.66886.54.
- Background: PubMed 24479675Pilsl U, Rosmarin W, Anderhuber F. The premaxillary space: a location for filler injection? Dermatol Surg. 2014 Mar;40(3):301-4. doi: 10.1111/dsu.12431. Epub 2014 Jan 30.
- Individual participant dataSharing planned: Yes. pilot study on 5 patients: min, max, average measurements will be published
Related trials for Atrophy
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Muscular Atrophy, Spinal
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joan H Vandeputte, MD principal investigator
A.Z Oudenaarde (Oudenaarde General Hospital)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hyaluronic Acid filler in people with Atrophy, run by Vandeputte, Joan, M.D. at 2 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
tissue inflammation after injection of hyaluronic acid filler (time frame: 3 weeks to 4 months after injection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02868749, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2019.